AMD: What’s in the Pipeline in 2023?
Provider: Mivision
Course Access: https://lms.optometry.org.au/course/view.php?id=597
Learning Objectives
- Understand the current burdens of treatment associated with AMD, nAMD, and GA
- Be aware of therapeutic drugs in the pipeline for treatment of AMD, nAMD, and GA, and their proposed mechanism of action
- Be aware of gene therapies being explored for AMD, nAMD, and GA
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| AMD: What’s in the Pipeline in 2023? |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |